A Pharmacokinetics Study of Favipiravir in Patients With Severe Influenza

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

February 6, 2018

Primary Completion Date

February 20, 2019

Study Completion Date

March 27, 2019

Conditions
Influenza, HumanCritical IllnessInfluenza
Interventions
DRUG

Favipiravir

"In first step: favipiravir tablet is orally administered. This drug will be given twice daily for a 10-day period. For the First day, the dosage is 1600 mg twice daily. Starting from the second day, the dosage is 600 mg twice daily.~In second step: favipiravir tablet is orally administered. This drug will be given twice daily for a 10-day period. For the First day, the dosage is 1800 mg twice daily. Starting from the second day, the dosage is 800 mg twice daily."

DRUG

Oseltamivir 75Mg Capsule

oseltamivir will be administered at 75mg twice daily orally for 10 days

Trial Locations (1)

100029

China-Japan Friendship Hospital, Beijing

All Listed Sponsors
collaborator

Beijing Institute of Pharmacology and Toxicology

OTHER

collaborator

University of Oxford

OTHER

collaborator

Centers for Disease Control and Prevention, China

OTHER_GOV

lead

Capital Medical University

OTHER

NCT03394209 - A Pharmacokinetics Study of Favipiravir in Patients With Severe Influenza | Biotech Hunter | Biotech Hunter